Baqsimi FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 6, 2020.
FDA Approved: Yes (First approved July 24, 2019)
Brand name: Baqsimi
Generic name: glucagon
Dosage form: Nasal Powder
Company: Eli Lilly and Company
Treatment for: Hypoglycemia
Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycemia in diabetes patients ages 4 years and older.
Development timeline for Baqsimi
|Jul 24, 2019||Approval FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.